BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

618 related articles for article (PubMed ID: 18838581)

  • 1. In vitro activities of doripenem, a new broad-spectrum carbapenem, against recently collected clinical anaerobic isolates, with emphasis on the Bacteroides fragilis group.
    Snydman DR; Jacobus NV; McDermott LA
    Antimicrob Agents Chemother; 2008 Dec; 52(12):4492-6. PubMed ID: 18838581
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lessons learned from the anaerobe survey: historical perspective and review of the most recent data (2005-2007).
    Snydman DR; Jacobus NV; McDermott LA; Golan Y; Hecht DW; Goldstein EJ; Harrell L; Jenkins S; Newton D; Pierson C; Rihs JD; Yu VL; Venezia R; Finegold SM; Rosenblatt JE; Gorbach SL
    Clin Infect Dis; 2010 Jan; 50 Suppl 1():S26-33. PubMed ID: 20067390
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In vitro activities of doripenem and comparator agents against 364 anaerobic clinical isolates.
    Wexler HM; Engel AE; Glass D; Li C
    Antimicrob Agents Chemother; 2005 Oct; 49(10):4413-7. PubMed ID: 16189137
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Multicentre survey of the in-vitro activity of seven antimicrobial agents, including ertapenem, against recently isolated Gram-negative anaerobic bacteria in Greece.
    Papaparaskevas J; Pantazatou A; Katsandri A; Legakis NJ; Avlamis A;
    Clin Microbiol Infect; 2005 Oct; 11(10):820-4. PubMed ID: 16153256
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In vitro activity of ertapenem: review of recent studies.
    Wexler HM
    J Antimicrob Chemother; 2004 Jun; 53 Suppl 2():ii11-21. PubMed ID: 15150179
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Doripenem (S-4661), a novel carbapenem: comparative activity against contemporary pathogens including bactericidal action and preliminary in vitro methods evaluations.
    Jones RN; Huynh HK; Biedenbach DJ; Fritsche TR; Sader HS
    J Antimicrob Chemother; 2004 Jul; 54(1):144-54. PubMed ID: 15190031
    [TBL] [Abstract][Full Text] [Related]  

  • 7. ["In vitro" activity of ten antimicrobial agents against anaerobic bacteria. A collaborative study, 1999-2002].
    Litterio M; Bianchini H; Carloni G; Di Martino A; Fernández Canigia L; Greco G; Legaria C; Rollet R; Rossetti A; Predari SC; Castello L
    Rev Argent Microbiol; 2004; 36(3):130-5. PubMed ID: 15559195
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Update on resistance of Bacteroides fragilis group and related species with special attention to carbapenems 2006-2009.
    Snydman DR; Jacobus NV; McDermott LA; Golan Y; Goldstein EJ; Harrell L; Jenkins S; Newton D; Pierson C; Rosenblatt J; Venezia R; Gorbach SL; Queenan AM; Hecht DW
    Anaerobe; 2011 Aug; 17(4):147-51. PubMed ID: 21664469
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Activity of a novel carbapenem, doripenem, against anaerobic pathogens.
    Goldstein EJ; Citron DM
    Diagn Microbiol Infect Dis; 2009 Apr; 63(4):447-54. PubMed ID: 19249176
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In vitro activity of Biapenem plus RPX7009, a carbapenem combined with a serine β-lactamase inhibitor, against anaerobic bacteria.
    Goldstein EJ; Citron DM; Tyrrell KL; Merriam CV
    Antimicrob Agents Chemother; 2013 Jun; 57(6):2620-30. PubMed ID: 23529731
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antimicrobial activity of doripenem (S-4661): a global surveillance report (2003).
    Fritsche TR; Stilwell MG; Jones RN
    Clin Microbiol Infect; 2005 Dec; 11(12):974-84. PubMed ID: 16307551
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In vitro potency of doripenem tested against an international collection of rarely isolated bacterial pathogens.
    Jones RN; Bell JM; Sader HS; Turnidge JD; Stilwell MG
    Diagn Microbiol Infect Dis; 2009 Apr; 63(4):434-9. PubMed ID: 19302927
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Selection of a surrogate beta-lactam testing agent for initial susceptibility testing of doripenem, a new carbapenem.
    Jones RN; Sader HS; Fritsche TR; Janechek MJ
    Diagn Microbiol Infect Dis; 2007 Dec; 59(4):467-72. PubMed ID: 17997070
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparative susceptibility of the Bacteroides fragilis group species and other anaerobic bacteria to meropenem, imipenem, piperacillin, cefoxitin, ampicillin/sulbactam, clindamycin and metronidazole.
    Goldstein EJ; Citron DM; Cherubin CE; Hillier SL
    J Antimicrob Chemother; 1993 Mar; 31(3):363-72. PubMed ID: 8486570
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of the in vitro activity of ertapenem and nine other comparator agents against 337 anaerobic bacteria.
    Behra-Miellet J; Dubreuil L; Calvet L
    Int J Antimicrob Agents; 2006 Jul; 28(1):25-35. PubMed ID: 16757152
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antimicrobial activity of doripenem tested against prevalent Gram-positive pathogens: results from a global surveillance study (2003-2007).
    Fritsche TR; Sader HS; Stillwell MG; Jones RN
    Diagn Microbiol Infect Dis; 2009 Apr; 63(4):440-6. PubMed ID: 19302928
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Increasing trends in antimicrobial resistance among clinically important anaerobes and Bacteroides fragilis isolates causing nosocomial infections: emerging resistance to carbapenems.
    Liu CY; Huang YT; Liao CH; Yen LC; Lin HY; Hsueh PR
    Antimicrob Agents Chemother; 2008 Sep; 52(9):3161-8. PubMed ID: 18625771
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Susceptibility trends of Bacteroides fragilis group and characterisation of carbapenemase-producing strains by automated REP-PCR and MALDI TOF.
    Treviño M; Areses P; Peñalver MD; Cortizo S; Pardo F; del Molino ML; García-Riestra C; Hernández M; Llovo J; Regueiro BJ
    Anaerobe; 2012 Feb; 18(1):37-43. PubMed ID: 22261518
    [TBL] [Abstract][Full Text] [Related]  

  • 19. National survey on the susceptibility of Bacteroides fragilis group: report and analysis of trends in the United States from 1997 to 2004.
    Snydman DR; Jacobus NV; McDermott LA; Ruthazer R; Golan Y; Goldstein EJ; Finegold SM; Harrell LJ; Hecht DW; Jenkins SG; Pierson C; Venezia R; Yu V; Rihs J; Gorbach SL
    Antimicrob Agents Chemother; 2007 May; 51(5):1649-55. PubMed ID: 17283189
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Activity of doripenem against anaerobic bacteria].
    Dubreuil L; Neut C; Mahieux S; Muller-Serieys C; Jean-Pierre H; Marchandin H; Soussy CJ; Miara A
    Pathol Biol (Paris); 2011 Apr; 59(2):102-7. PubMed ID: 20537808
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 31.